Table 3.

Combined effect of aspirin compared to placebo on risk of cardiovascular disease, myocardial infarction, and stroke by GUCY1A3 rs7692387 genotype strata in Women’s Genome Health Study and Physician’s Health Study^a

Outcome	Trial	rs7692387	Events/N cases/controls	OR (95% CI)b	P-value	I2
CVD	WGHS	G/G	335/14 849	0.83 (0.66–1.03)	0.09
	PHS	G/G	154/195	0.63 (0.38–1.03)	0.07
	Overallc	G/G		0.79 (0.65–0.97)	0.03	0
	WGHS	G/A	99/6962	1.38 (1.00–1.91)	0.05
	PHS	G/A	68/81	1.42 (0.66–3.05)	0.37
	Overall	G/A		1.39 (1.03–1.87)	0.03	0
MI	WGHS	G/G	137/14 849	0.85 (0.61–1.20)	0.36
	PHS	G/G	110/136	0.58 (0.31–1.05)	0.07
	Overall	G/G		0.77 (0.55–1.07	0.12	13
	WGHS	G/A	64/6962	1.28 (0.78–2.11)	0.33
	PHS	G/A	48/53	2.24 (0.90–5.59)	0.08
	Overall	G/A		1.48 (0.92–2.38)	0.11	10
Stroke	WGHS	G/G	138/14 849	0.74 (0.53–1.04)	0.08
	PHS	G/G	44/59	0.76 (0.30–1.91)	0.56
	Overall	G/G		0.74 (0.54–1.02)	0.07	0
	WGHS	G/A	67/6962	1.09 (0.67–1.77)	0.72
	PHS	G/A	20/28	0.32 (0.06–1.82)	0.20
	Overall	G/A		0.99 (0.62–1.59)	0.98	46

^aWhite cases and controls before 25 January 1988.

^bOdd ratios were estimated from logistic models. Models were adjusted for randomized treatment assignment, age, and smoking.

^cRandom effects meta-analysis.